Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab [11]

Leukemia

Volumn 21, Issue 8, 2007, Pages 1841-1842

  Royer, B ^a   Vaida, I ^a   Etienne, A ^a   Garidi, R ^a   Damaj, G ^a   Marolleau, J P ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FLUDARABINE; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB;

ABSENCE OF SIDE EFFECTS; AGED; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TRANSFUSION; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; COOMBS TEST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; PRIORITY JOURNAL; RECURRENT DISEASE; SPLENECTOMY;

EID: 34447638712     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404713     Document Type: Letter

References (3)

1. Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007; 21: 511-514.
2. Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic and prognostic features. Blood 2000; 95 2786-2792.
3. Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004; 72: 79-88.